scholarly journals A Reanalysis of IgM Western Blot Criteria for the Diagnosis of Early Lyme Disease

1999 ◽  
Vol 179 (4) ◽  
pp. 1021-1024 ◽  
Author(s):  
Richard Porwancher
Keyword(s):  
Lyme Disease ◽  
Western Blot

scholarly journals Quality Control Assessment of Canadian Laboratories Testing for Lyme Disease

1991 ◽  
Vol 2 (1) ◽  
pp. 41-45
Author(s):  
Harvey Artsob ◽  
Maxwell Garvie
Keyword(s):  
Public Health ◽  
Quality Control ◽  
Lyme Disease ◽  
Borrelia Burgdorferi ◽  
Western Blot ◽  
Etiological Agent ◽  
Immunofluorescent Assay ◽  
Satisfactory Performance ◽  
Endemic Areas ◽  
Negative Controls

In June 1990 a quality control assessment was undertaken of Canadian public health laboratories testing for antibodies toBorrelia burgdorferi, the etiological agent of Lyme disease. Twenty sera were distributed to nine laboratories, including 12 obtained from patients in Lyme endemic areas and presumed to be serological positives, and eight prescreened negative controls. Seventeen serological reports were submitted, comprising nine enzyme-linked immunosorbent assays (elisa), six immunofluorescent assays and two Western blot assessments. Antibodies were detected in 11 of the 12 sera which had been presumed to be positive. Assuming 11 positive sera had been submitted, the test sensitivities varied from 88.9 to 100% byelisa, and 54.5 to 90.1% by immunofluorescent assay. Specificities were 100% for all but oneelisaand one immunofluorescent assay assessment. The results indicate a satisfactory performance byelisabut a need for upgrading or replacement of some immunofluorescent assay tests.

scholarly journals Borrelia burgdorferi and Borrelia miyamotoi seroprevalence in California blood donors

PLoS ONE ◽  
2020 ◽  
Vol 15 (12) ◽  
pp. e0243950
Author(s):  
Sharon I. Brummitt ◽  
Anne M. Kjemtrup ◽  
Danielle J. Harvey ◽  
Jeannine M. Petersen ◽  
Christopher Sexton ◽  
...  
Keyword(s):  
Lyme Disease ◽  
Borrelia Burgdorferi ◽  
Western Blot ◽  
Sierra Nevada ◽  
Blood Donors ◽  
Test System ◽  
Emerging Diseases ◽  
Borrelia Miyamotoi ◽  
Increased Risk ◽  
Significant Difference

The western blacklegged tick, Ixodes pacificus, an important vector in the western United States of two zoonotic spirochetes: Borrelia burgdorferi (also called Borreliella burgdorferi), causing Lyme disease, and Borrelia miyamotoi, causing a relapsing fever-type illness. Human cases of Lyme disease are well-documented in California, with increased risk in the north coastal areas and western slopes of the Sierra Nevada range. Despite the established presence of B. miyamotoi in the human-biting I. pacificus tick in California, clinical cases with this spirochete have not been well studied. To assess exposure to B. burgdorferi and B. miyamotoi in California, and to address the hypothesis that B. miyamotoi exposure in humans is similar in geographic range to B. burgdorferi, 1,700 blood donor sera from California were tested for antibodies to both pathogens. Sampling was from high endemic and low endemic counties for Lyme disease in California. All sera were screened using the C6 ELISA. All C6 positive and equivocal samples and nine randomly chosen C6 negative samples were further analyzed for B. burgdorferi antibody using IgG western blot and a modified two ELISA test system and for B. miyamotoi antibody using the GlpQ ELISA and B. miyamotoi whole cell sonicate western blot. Of the 1,700 samples tested in series, eight tested positive for antibodies to B. burgdorferi (0.47%, Exact 95% CI: 0.20, 0.93) and two tested positive for antibodies to B. miyamotoi (0.12%, Exact 95% CI: 0.01, 0.42). There was no statistically significant difference in seroprevalence for either pathogen between high and low Lyme disease endemic counties. Our results confirm a low frequency of Lyme disease and an even lower frequency of B. miyamotoi exposure among adult blood donors in California; however, our findings reinforce public health messaging that there is risk of infection by these emerging diseases in the state.

Potentially misleading Western blot results in Lyme disease diagnosis

2006 ◽  
Vol 63 (3) ◽  
pp. 142-144
Author(s):  
S. Mavin ◽  
R. Evans ◽  
K. Appleyard ◽  
A.W.L. Joss ◽  
D.O. Ho-Yen
Keyword(s):  
Lyme Disease ◽  
Western Blot ◽  
Disease Diagnosis

scholarly journals Western blot method as a necessary step of serodiagnostics of Lyme disease

2012 ◽  
Vol 5 ◽  
pp. 397-402
Author(s):  
Jacek Noworyta ◽  
Maja Machcińska ◽  
Maria Brasse-Rumin ◽  
Jakub Ząbek ◽  
Jolanta Gago
Keyword(s):  
Lyme Disease ◽  
Western Blot ◽  
Western Blot Method

Antiphospholipid antibodies in patients with purported ‘chronic Lyme disease’

Lupus ◽  
2011 ◽  
Vol 20 (13) ◽  
pp. 1372-1377 ◽  
Author(s):  
TP Greco ◽  
AM Conti-Kelly ◽  
TP Greco
Keyword(s):  
Lyme Disease ◽  
Western Blot ◽  
Antiphospholipid Antibodies ◽  
Lupus Anticoagulant ◽  
Anticardiolipin Antibodies ◽  
Enzyme Linked Immunosorbent Assay ◽  
Antiphospholipid Antibody ◽  
Chronic Lyme Disease ◽  
Beta 2

Background: Antiphospholipid antibody (aPL) positive patients and patients with purported chronic Lyme disease (‘CLD’) share many clinical features. After identifying significant aPL in sera of several index patients with ‘CLD’, we performed aPL tests on all patients referred inwhom ‘CLD’ was suspected, diagnosed or treated. Methods: All patients with suspected, diagnosed or treated ‘CLD’ and reportedly ‘positive’ Lyme assays were studied. aPL testing included anticardiolipin antibodies (aCL), anti-beta-2-glycoprotein-1 antibodies (anti-β2GP1) and lupus anticoagulant (LAC). Patients were classified into four newly described categories of CLD and data was analyzed. Results: One hundred and six patients were evaluated, of whom 82% had neurologic symptoms and 51% rheumatologic symptoms. Eighty-eight of 106 (83%) patients had positive Lyme serologies (enzyme-linked immunosorbent assay [ELISA] 62/106, 58.4%; western blot [WB] 64/106, 60%), while 18/106 (16.9%) were negative or equivocal. aPL was found in all ‘CLD’ categories. aCL and/or anti-β2GP1 were positive in 85/106 (80%), with aCL present in 69/106 (65%) and anti-β2GP1 present in 69/106 (65%). For all assays, IgM isotypes predominated: WB 55/64 (85%), aCL 63/69 (91%), anti-β2GP1 52/69 (75%), aCL and/or anti-β2GP1 74/85 (87%). Anti-β2GP1 assays occurred in higher titer than aCL: 36/69 (52%) versus 63/69 (91%), p<0.001. Seventeen patients had aPL-related events. Only 12/106 (11.3%) had true post-Lyme syndromes (PLS), category IV, or late Lyme disease (LLD). Most patients had been treated for Lyme: 82/106 (79%). Conclusion: aPL occurs frequently in patients with ‘CLD’. IgM anti-β2GP1, IgM aCL and IgM WB were frequently found. Documented PLS or LLD was uncommon. The role of aPL in patients with ‘CLD’ needs further investigation. Lupus (2011) 20, 1372–1377.

scholarly journals 603. Misdiagnosis of Lyme Disease in Patients Referred to an Academic Lyme Center

2021 ◽  
Vol 8 (Supplement_1) ◽  
pp. S404-S404
Author(s):  
Kalpana D Shere-Wolfe ◽  
Rachel Silk ◽  
Mia Lynch ◽  
Adrian Jones-Dove ◽  
Carla Alexander
Keyword(s):  
Lyme Disease ◽  
Western Blot ◽  
Laboratory Testing ◽  
Healthcare Providers ◽  
Clinical History ◽  
Medical Doctor ◽  
Care Physician ◽  
Laboratory Test Results ◽  
Patient Reported ◽  
Epidemiologic Risk

Abstract Background Confusion and controversy surround various aspects of Lyme Disease (LD) including diagnosis. Typically, the diagnosis of LD is based on tick exposure, clinical history, exam, and laboratory testing. Laboratory testing and interpretation can be confusing, difficult, and a source of misdiagnosis. Methods One hundred and fifteen records of patients referred to the Integrated Lyme Program at University of Maryland for evaluation of LD were analyzed. All patients underwent initial evaluation by Infectious Disease (ID) physician who made a determination regarding Lyme diagnosis based on history, exam, epidemiologic risk factors and laboratory test results. Pt were determined to have one of the following diagnoses: 1) Acute LD 2) Past LD 3) Post Treatment Lyme Disease Syndrome (PTLDS) 4) Misdiagnosed LD. Data was also collected on reasons for misdiagnosis based on record review, referral information and patient reported information. Results We evaluated 115 patient records from our Lyme Program Registry. There were 78 female (68%) and 37 males (32%). The mean age was 46 years (range 19 to 83). Of the 115 records analyzed, there were 8 (7%) patients with acute Lyme disease; 38 (33%) patients with past Lyme disease , 3 (2.6%) patients with PTLDS and 93 (81%) of patients who were misdiagnosed with LD. Patients were misdiagnosed for multiple reasons and by different people. Twenty three percent (21/93) were misdiagnosed based on false positive IGM Western Blot; 16% (15/93) were misdiagnosed based on misread IGG Western Blot and 14% (13/93) were misdiagnosed based on unconventional Lyme test. The remainder were misdiagnosed based on symptoms. Forty two percent (39/93) were misdiagnosed by PCP; 4.3%(3/93) were misdiagnosed by Urgent/Emergent care physician and 31% (29/93) were misdiagnosed by physicians’ self-referred as Lyme Literate Medical Doctor. The remainder were incorrectly self-diagnosed by patients based on symptoms. Conclusion Misdiagnosis of patients referred to Lyme Center is common and due to various reasons including misinterpretation of laboratory Lyme testing by healthcare providers and misinterpretation of symptoms by patients. Disclosures All Authors: No reported disclosures

Comparison of western blot and microimmunofluorescence as tools for lyme disease seroepidemiology

1993 ◽  
Vol 9 (3) ◽  
pp. 269-273 ◽  
Author(s):  
J. P. Arzouni ◽  
M. Laveran ◽  
J. Beytout ◽  
O. Ramousse ◽  
D. Raoult
Keyword(s):  
Lyme Disease ◽  
Western Blot

scholarly journals Significantly Improved Accuracy of Diagnosis of Early Lyme Disease by Peptide Enzyme-Linked Immunosorbent Assay Based on the Borreliacidal Antibody Epitope of Borrelia burgdorferi OspC

2008 ◽  
Vol 15 (6) ◽  
pp. 981-985 ◽  
Author(s):  
Dean A. Jobe ◽  
Steven D. Lovrich ◽  
Krista E. Asp ◽  
Michelle A. Mathiason ◽  
Stephanie E. Albrecht ◽  
...  
Keyword(s):  
Lyme Disease ◽  
Borrelia Burgdorferi ◽  
Western Blot ◽  
Immunosorbent Assay ◽  
Antibody Test ◽  
Immunoglobulin M ◽  
Enzyme Linked Immunosorbent Assay ◽  
C Terminus ◽  
Igm Elisa ◽  
Improved Accuracy

ABSTRACT Highly specific borreliacidal antibodies are induced by infection with Borrelia burgdorferi, and the immunodominant response during early Lyme disease is specific for an epitope within the 7 amino acids nearest the C terminus of OspC. We evaluated the ability of an enzyme-linked immunosorbent assay (ELISA) based on a synthetic peptide (OspC7) that matched the region to detect the response and compared the sensitivity during early Lyme disease to that for an FDA-approved Western blot. When the optical density value was adjusted to 98% specificity based on the results from testing normal or uncharacterized sera (n = 236) or sera from patients with blood factors or illnesses that commonly produce antibodies that cross-react with B. burgdorferi antigens (n = 77), 115 (73%) of 157 sera from patients likely to have early Lyme disease were positive for immunoglobulin M (IgM) antibodies and 17 (11%) also had IgG antibodies. In addition, the IgM ELISA reactivities and the titers of antibodies detected by a flow cytometric borreliacidal antibody test correlated closely (r = 0.646). Moreover, the IgM ELISA was significantly more sensitive (P < 0.001) than the Western blot procedure. The findings therefore confirmed that the peptide IgM ELISA detected OspC borreliacidal antibodies and provided strong evidence that the test can eliminate the necessity for confirming early Lyme disease by a supplementary test such as Western blotting.

scholarly journals Long-Term Effects of Immunization with Recombinant Lipoprotein Outer Surface Protein A on Serologic Test for Lyme Disease

2004 ◽  
Vol 11 (4) ◽  
pp. 808-810 ◽  
Author(s):  
Paul T. Fawcett ◽  
Carlos D. Rose ◽  
Victoria Maduskuie
Keyword(s):  
Lyme Disease ◽  
Western Blot ◽  
Outer Surface ◽  
Protein A ◽  
Surface Protein ◽  
Long Term Effects ◽  
Serologic Test ◽  
Outer Surface Protein A ◽  
Outer Surface Protein

ABSTRACT Immunization with recombinant lipoprotein outer surface protein A vaccine is known to interfere with some serologic tests for Lyme disease. We tested sera from 152 vaccine recipients by using in-house and commercial Western blot assays and found that vaccination caused interference in up to 25% of recipients and can persist for over 6 years.

Sign in / Sign up

Export Citation Format

Share Document